p.94 抽出テキスト

650. Otto CM, Davis KB, Reid CL, Slater JN, Kronzon I, Kisslo KB, et al. Relation between pulmonary artery pressure and mitral stenosis severity in patients undergoing balloon mitral commissurotomy. Am J Cardiol 1993;71:874–8. https://doi.org/10.1016/0002- 9149(93)90844-3 651. Bouleti C, Iung B, Laouenan C, Himbert D, Brochet E, Messika-Zeitoun D, et al. Late results of percutaneous mitral commissurotomy up to 20 years: development and validation of a risk score predicting late functional results from a series of 912 patients. Circulation 2012;125:2119–27. https://doi.org/10.1161/CIRCULATIONAHA.111. 055905 652. Nunes MC, Tan TC, Elmariah S, do Lago R, Margey R, Cruz-Gonzalez I, et al. The echo score revisited: impact of incorporating commissural morphology and leaflet displacement to the prediction of outcome for patients undergoing percutaneous mitral valvuloplasty. Circulation 2014;129:886–95. https://doi.org/10.1161/CIRCULATION AHA.113.001252 653. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988;60:299–308. https://doi.org/10. 1136/hrt.60.4.299 654. Lancellotti P, Pellikka PA, Budts W, Chaudhry FA, Donal E, Dulgheru R, et al. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2016;17:1191–229. https://doi.org/ 10.1093/ehjci/jew190 655. Brochet E, Détaint D, Fondard O, Tazi-Mezalek A, Messika-Zeitoun D, Iung B, et al. Early hemodynamic changes versus peak values: what is more useful to predict occurrence of dyspnea during stress echocardiography in patients with asymptomatic mitral stenosis? J Am Soc Echocardiogr 2011;24:392–8. https://doi.org/10.1016/j.echo.2011.01. 006 656. Al Rawahi MN, Al-Maqbali JS, Al Noumani J, Al Alawi AM, Essebag V. Novel oral anticoagulants in patients with atrial fibrillation and moderate to severe mitral stenosis: a systematic review. Cureus 2023;15:e33222. https://doi.org/10.7759/cureus.33222 657. Kim JY, Kim SH, Myong JP, Kim YR, Kim TS, Kim JH, et al. Outcomes of direct oral anticoagulants in patients with mitral stenosis. J Am Coll Cardiol 2019;73:1123–31. https:// doi.org/10.1016/j.jacc.2018.12.047 658. Vilvanathan VK, Srinivas Prabhavathi Bhat BC, Nanjappa MC, Pandian B, Bagi V, Kasturi S, et al. A randomized placebo-controlled trial with amiodarone for persistent atrial fibrillation in rheumatic mitral stenosis after successful balloon mitral valvuloplasty. Indian Heart J 2016;68:671–7. https://doi.org/10.1016/j.ihj.2016.02.013 659. Sharma G, Anantha Krishnan R, Bohra V, Ramakrishnan S, Naik N, Seth S, et al. Evaluation of early direct current cardioversion for maintenance of sinus rhythm in rheumatic atrial fibrillation following successful balloon mitral valvotomy. Indian Heart J 2016;68:486–92. https://doi.org/10.1016/j.ihj.2015.11.013 660. Keenan NG, Cueff C, Cimadevilla C, Brochet E, Lepage L, Detaint D, et al. Usefulness of left atrial volume versus diameter to assess thromboembolic risk in mitral stenosis. Am J Cardiol 2010;106:1152–6. https://doi.org/10.1016/j.amjcard.2010.06.024 661. Badheka AO, Shah N, Ghatak A, Patel NJ, Chothani A, Mehta K, et al. Balloon mitral valvuloplasty in the United States: a 13-year perspective. Am J Med 2014;127: 1126.e1121–1126.e1112. https://doi.org/10.1016/j.amjmed.2014.05.015 662. Tomai F, Gaspardone A, Versaci F, Ghini AS, Altamura L, De Luca L, et al. Twenty year follow-up after successful percutaneous balloon mitral valvuloplasty in a large contemporary series of patients with mitral stenosis. Int J Cardiol 2014;177:881–5. https://doi. org/10.1016/j.ijcard.2014.10.040 663. Bouleti C, Iung B, Himbert D, Messika-Zeitoun D, Brochet E, Garbarz E, et al. Relationship between valve calcification and long-term results of percutaneous mitral commissurotomy for rheumatic mitral stenosis. Circ Cardiovasc Interv 2014;7:381–9. https://doi.org/10.1161/CIRCINTERVENTIONS.113.000858 664. Bouleti C, Iung B, Himbert D, Brochet E, Messika-Zeitoun D, Detaint D, et al. Reinterventions after percutaneous mitral commissurotomy during long-term followup, up to 20 years: the role of repeat percutaneous mitral commissurotomy. Eur Heart J 2013;34:1923–30. https://doi.org/10.1093/eurheartj/eht097 665. Desnos C, Iung B, Himbert D, Ducrocq G, Urena M, Cormier B, et al. Temporal trends on percutaneous mitral commissurotomy: 30 years of experience. J Am Heart Assoc 2019;8:e012031. https://doi.org/10.1161/JAHA.119.012031 666. Ambari AM, Setianto B, Santoso A, Dwiputra B, Radi B, Alkatiri AA, et al. Survival analysis of patients with rheumatic MS after PBMV compared with MVS in a low-to-middle-income country. Neth Heart J 2019;27:559–64. https://doi.org/10. 1007/s12471-019-01315-x 667. Song H, Kang DH, Kim JH, Park KM, Song JM, Choi KJ, et al. Percutaneous mitral valvuloplasty versus surgical treatment in mitral stenosis with severe tricuspid regurgitation. Circulation 2007;116:I246–50. https://doi.org/10.1161/CIRCULATIONAHA.107. 678151 668. Soesanto AM, Roeswita D, Atmosudigdo IS, Adiarto S, Sahara E. Clinical and hemodynamic factors associated with low gradient severe rheumatic mitral stenosis. Int J Angiol 2022;32:43–7. https://doi.org/10.1055/s-0042-1751231 669. El Sabbagh A, Reddy YNV, Barros-Gomes S, Borlaug BA, Miranda WR, Pislaru SV, et al. Low-gradient severe mitral stenosis: hemodynamic profiles, clinical characteristics, and outcomes. J Am Heart Assoc 2019;8:e010736. https://doi.org/10.1161/JAHA.118. 010736 670. Okura H, Nakada Y, Nogi M, Ishihara S, Okamura A, Okayama S, et al. Prevalence of mitral annular calcification and its association with mitral valvular disease. Echocardiography 2021;38:1907–12. https://doi.org/10.1111/echo.15236 671. Kato N, Padang R, Scott CG, Guerrero M, Pislaru SV, Pellikka PA. The natural history of severe calcific mitral stenosis. J Am Coll Cardiol 2020;75:3048–57. https://doi.org/10. 1016/j.jacc.2020.04.049 672. Chehab O, Roberts-Thomson R, Bivona A, Gill H, Patterson T, Pursnani A, et al. Management of patients with severe mitral annular calcification: JACC state-of-the-art review. J Am Coll Cardiol 2022;80:722–38. https://doi.org/10.1016/j.jacc.2022.06.009 673. Okuno T, Brugger N, Asami M, Heg D, Siontis GCM, Winkel MG, et al. Clinical impact of mitral calcium volume in patients undergoing transcatheter aortic valve implantation. J Cardiovasc Comput Tomogr 2021;15:356–65. https://doi.org/10.1016/j.jcct. 2020.10.003 674. Bertrand PB, Churchill TW, Yucel E, Namasivayam M, Bernard S, Nagata Y, et al. Prognostic importance of the transmitral pressure gradient in mitral annular calcification with associated mitral valve dysfunction. Eur Heart J 2020;41:4321–8. https://doi. org/10.1093/eurheartj/ehaa819 675. Urena M, Himbert D, Brochet E, Carrasco JL, Iung B, Nataf P, et al. Transseptal transcatheter mitral valve replacement using balloon-expandable transcatheter heart valves: a step-by-step approach. JACC Cardiovasc Interv 2017;10:1905–19. https://doi.org/10. 1016/j.jcin.2017.06.069 676. Guerrero ME, Grayburn P, Smith RLI, Sorajja P, Wang DD, Ahmad Y, et al. Diagnosis, classification, and management strategies for mitral annular calcification. JACC Cardiovasc Interv 2023;16:2195–210. https://doi.org/10.1016/j.jcin.2023.06.044 677. Uchimuro T, Fukui T, Shimizu A, Takanashi S. Mitral valve surgery in patients with severe mitral annular calcification. Ann Thorac Surg 2016;101:889–95. https://doi.org/10. 1016/j.athoracsur.2015.08.071 678. Fukui M, Cavalcante JL, Ahmed A, Bae R, Bapat VN, Gössl M, et al. Clinical outcomes of mitral valve disease with mitral annular calcification. Am J Cardiol 2022;174:107–13. https://doi.org/10.1016/j.amjcard.2022.03.041 679. Kato N, Pellikka PA, Scott CG, Lee AT, Jain V, Eleid MF, et al. Impact of mitral intervention on outcomes of patients with mitral valve dysfunction and annulus calcification. Catheter Cardiovasc Interv 2022;99:1807–16. https://doi.org/10.1002/ccd.30093 680. Brener MI, Hamandi M, Hong E, Pizano A, Harloff MT, Garner EF, et al. Early outcomes following transatrial transcatheter mitral valve replacement in patients with severe mitral annular calcification. J Thorac Cardiovasc Surg 2024;167:1263–1275.e3. https://doi. org/10.1016/j.jtcvs.2022.07.038 681. Guerrero ME, Eleid MF, Wang DD, Pursnani A, Kodali SK, George I, et al. 5-Year prospective evaluation of mitral valve-in-valve, valve-in-ring, and valve-in-MAC outcomes: MITRAL trial final results. JACC Cardiovasc Interv 2023;16:2211–27. https://doi.org/10. 1016/j.jcin.2023.06.041 682. Topilsky Y, Maltais S, Medina Inojosa J, Oguz D, Michelena H, Maalouf J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging 2019;12:433–42. https://doi.org/10.1016/j.jcmg.2018.06.014 683. Chorin E, Rozenbaum Z, Topilsky Y, Konigstein M, Ziv-Baran T, Richert E, et al. Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc Imaging 2020;21:157–65. https://doi.org/10.1093/ehjci/jez216 684. Topilsky Y, Inojosa JM, Benfari G, Vaturi O, Maltais S, Michelena H, et al. Clinical presentation and outcome of tricuspid regurgitation in patients with systolic dysfunction. Eur Heart J 2018;39:3584–92. https://doi.org/10.1093/eurheartj/ehy434 685. Kadri AN, Menon V, Sammour YM, Gajulapalli RD, Meenakshisundaram C, Nusairat L, et al. Outcomes of patients with severe tricuspid regurgitation and congestive heart failure. Heart 2019;105:1813–7. https://doi.org/10.1136/heartjnl-2019-315004 686. Dreyfus J, Ghalem N, Garbarz E, Cimadevilla C, Nataf P, Vahanian A, et al. Timing of referral of patients with severe isolated tricuspid valve regurgitation to surgeons (from a French nationwide database). Am J Cardiol 2018;122:323–6. https://doi.org/ 10.1016/j.amjcard.2018.04.003 687. Hoke U, Auger D, Thijssen J, Wolterbeek R, van der Velde ET, Holman ER, et al. Significant lead-induced tricuspid regurgitation is associated with poor prognosis at long-term follow-up. Heart 2014;100:960–8. https://doi.org/10.1136/heartjnl-2013- 304673 688. Andreas M, Burri H, Praz F, Soliman O, Badano L, Barreiro M, et al. Tricuspid valve disease and cardiac implantable electronic devices. Eur Heart J 2024;45:346–65. https:// doi.org/10.1093/eurheartj/ehad783 689. Praz F, Muraru D, Kreidel F, Lurz P, Hahn RT, Delgado V, et al. Transcatheter treatment for tricuspid valve disease. EuroIntervention 2021;17:791–808. https://doi.org/ 10.4244/EIJ-D-21-00695 690. Song H, Kim MJ, Chung CH, Choo SJ, Song MG, Song JM, et al. Factors associated with development of late significant tricuspid regurgitation after successful left-sided valve surgery. Heart 2009;95:931–6. https://doi.org/10.1136/hrt.2008.152793 691. Galloo X, Dietz MF, Fortuni F, Prihadi EA, Cosyns B, Delgado V, et al. Prognostic implications of atrial vs. ventricular functional tricuspid regurgitation. Eur Heart J Cardiovasc Imaging 2023;24:733–41. https://doi.org/10.1093/ehjci/jead016 Downloaded from academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 07 October 2026